ABCL Valuation

Abcellera Biologics Inc

Add to Watchlist

Advanced Chart

4.670

+0.08(1.743%)1D

Overview
Forecast
Valuation
Earnings

ABCL Relative Valuation

ABCL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABCL is overvalued; if below, it's undervalued.

Historical Valuation

Abcellera Biologics Inc (ABCL) is now in the Fair zone, suggesting that its current forward PS ratio of 20.37 is considered Fairly compared with the five-year average of 11.91. The fair price of Abcellera Biologics Inc (ABCL) is between 2.78 to 8.96 according to relative valuation methord.

Relative Value

Fair Zone

2.78-8.96

Current Price：4.67

Fair

-8.79

Trailing

Forward

-2.50

EV/EBITDA

Abcellera Biologics Inc. (ABCL) has a current EV/EBITDA of -2.50. The 5-year average EV/EBITDA is 8.53. The thresholds are as follows: Strongly Undervalued below -107.89, Undervalued between -107.89 and -49.68, Fairly Valued between 66.74 and -49.68, Overvalued between 66.74 and 124.95, and Strongly Overvalued above 124.95. The current Forward EV/EBITDA of -2.50 falls within the Historic Trend Line -Fairly Valued range.

-3.15

EV/EBIT

Abcellera Biologics Inc. (ABCL) has a current EV/EBIT of -3.15. The 5-year average EV/EBIT is 18.76. The thresholds are as follows: Strongly Undervalued below -207.45, Undervalued between -207.45 and -94.35, Fairly Valued between 131.86 and -94.35, Overvalued between 131.86 and 244.96, and Strongly Overvalued above 244.96. The current Forward EV/EBIT of -3.15 falls within the Historic Trend Line -Fairly Valued range.

20.37

Abcellera Biologics Inc. (ABCL) has a current PS of 20.37. The 5-year average PS is 30.48. The thresholds are as follows: Strongly Undervalued below -3.23, Undervalued between -3.23 and 13.62, Fairly Valued between 47.33 and 13.62, Overvalued between 47.33 and 64.18, and Strongly Overvalued above 64.18. The current Forward PS of 20.37 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Abcellera Biologics Inc. (ABCL) has a current P/OCF of 0.00. The 5-year average P/OCF is 14.53. The thresholds are as follows: Strongly Undervalued below -55.19, Undervalued between -55.19 and -20.33, Fairly Valued between 49.39 and -20.33, Overvalued between 49.39 and 84.25, and Strongly Overvalued above 84.25. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

8.49

P/FCF

Abcellera Biologics Inc. (ABCL) has a current P/FCF of 8.49. The 5-year average P/FCF is 11.61. The thresholds are as follows: Strongly Undervalued below -204.18, Undervalued between -204.18 and -96.29, Fairly Valued between 119.50 and -96.29, Overvalued between 119.50 and 227.40, and Strongly Overvalued above 227.40. The current Forward P/FCF of 8.49 falls within the Historic Trend Line -Fairly Valued range.

Abcellera Biologics Inc (ABCL) has a current Price-to-Book (P/B) ratio of 1.35. Compared to its 3-year average P/B ratio of 1.34 , the current P/B ratio is approximately 0.55% higher. Relative to its 5-year average P/B ratio of 14.06, the current P/B ratio is about -90.38% higher. Abcellera Biologics Inc (ABCL) has a Forward Free Cash Flow (FCF) yield of approximately -10.13%. Compared to its 3-year average FCF yield of -9.18%, the current FCF yield is approximately 10.41% lower. Relative to its 5-year average FCF yield of -4.20% , the current FCF yield is about 141.28% lower.

1.35

P/B

Median3y

1.34

Median5y

14.06

-10.13

FCF Yield

Median3y

-9.18

Median5y

-4.20

Competitors Valuation Multiple

The average P/S ratio for ABCL's competitors is 5.32, providing a benchmark for relative valuation. Abcellera Biologics Inc Corp (ABCL) exhibits a P/S ratio of 20.37, which is 282.80% above the industry average. Given its robust revenue growth of 133.29%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ABCL.O

Abcellera Biologics Inc

Vera Therapeutics Inc

Loss

1.39B

SNDX.O

Syndax Pharmaceuticals Inc

Dynavax Technologies Corp

Edgewise Therapeutics Inc

Loss

1.47B

Performance Decomposition

Market capitalization of ABCL increased by 82.42% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 7.32M to 17.08M.

The secondary factor is the P/E Change, contributed 8.82%to the performance.

Overall, the performance of ABCL in the past 1 year is driven by Revenue Growth. Which is more sustainable.

133.29%

7.32M → 17.08M

Revenue Growth

-59.69%

-504.30 → -203.27

Margin Expansion

8.82%

-7.56 → -8.23

P/E Change

82.42%